Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RLFTF On Linkedin 1 hr ago: Jake Clopton: Gilles DELLA CORTE do you expect covid mutations to potentially change the effectiveness of RLF-100 or is it expected to be effective regardless of variant?
Answer by Gilles DELLA CORTE
Jake Clopton no aviptadil, in the opposite to a vaccine, does not need to identify the spike protein to work so no reason to believe that a mutation at this level could jeopardize the efficacy
DD by Vincent
MM want shares.. shake 'n fake IMO
Interesting.. especially when we'll be getting a bigger slice of the pie.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
------
$RLFTF The Math
GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ --
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) Relief Therapeutics and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil)
(Zyesami ) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
$RLFTF The Math
GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ --
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) Relief Therapeutics and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil)
(Zyesami ) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
It takes an American to get the job done.
..he and many others went elsewhere.. turned off by...
..just stay away from Pens.. ;)
..could be uncle gee gee..
.. don't think they give out those wishes.. better off wishing for a Mansion or a Beach house.. ;) next to one of theirs in the Hamptons
..money will flow back into these solid runners.. the heat is coming off the "pants w/legs cut off" ROBINHOOD PLACING FREEZES AND SEIZING CAPITAL ON ACCOUNTS THEY SUSPECT OF MARKET MANIPULATION PER SEC ORDER
..heat is coming off the shorts.. "ROBINHOOD PLACING FREEZES AND SEIZING CAPITAL ON ACCOUNTS THEY SUSPECT OF MARKET MANIPULATION PER SEC ORDER"
$RLFTF Weekend news ? ..to hit ALL the outlets.. mmH Pound Cakes in the oven !!!
$APYP News link on OTC Market
https://www.otcmarkets.com/stock/APYP/news/APYP-begin-process-for-Acquisition-of-SleepX-Ltd?id=287757
APYP begin process for Acquisition of SleepX Ltd.
Press Release | 01/28/2021
AppYea, Inc begins the process to acquire Sleepx Ltd. and Nexense Technologies USA Inc.
Boca Raton, FL, and Rehovot, Israel (OTC Pink: APYP) AppYea, Inc. ("AppYea" or the "Company") begun the process to acquire 100% of the outstanding shares of SleepX Ltd., a company formed under the laws of Israel ("SleepX") and Nexense Technologies USA Inc., a Delaware corporation.
Todd Violette, CEO of AppYea stated, "I have been very impressed with the SleepX management team in Israel and SleepXs products and technology. SleepX holds a portfolio of patents and products designed to prevent snoring and sleep apnea, which I believe present a unique opportunity for AppYea." (cont'd)
$MSTO News Article - MasterBeat Corporation's JTEC Automotive Collaborates With Epicor and Hollander to Incorporate the World's Most Extensive New and Used Auto Parts and Accessories Database Via Its Online Platform.
https://marketwirenews.com/news-releases/masterbeat-corporation-s-jtec-automotive-collaborate-6222612329064846.html
$MSTO News Article - MasterBeat Corporation's JTEC Automotive Collaborates With Epicor and Hollander to Incorporate the World's Most Extensive New and Used Auto Parts and Accessories Database Via Its Online Platform.
https://marketwirenews.com/news-releases/masterbeat-corporation-s-jtec-automotive-collaborate-6222612329064846.html
$RLFTF On Linkedin 1 hr ago: Jake Clopton: Gilles DELLA CORTE do you expect covid mutations to potentially change the effectiveness of RLF-100 or is it expected to be effective regardless of variant?
Answer by Gilles DELLA CORTE
Jake Clopton no aviptadil, in the opposite to a vaccine, does not need to identify the spike protein to work so no reason to believe that a mutation at this level could jeopardize the efficacy
DD by Vincent
..grabbed a bunch a .0012's myself today.. this guy is handling this company like a darling it seems.. maybe he wants to retire and this is the big bang..??
Buying More !!!
$RLFTF ..should be moving up on FOMO now.. ;) We Got The Jewels !!
$RLFTF (copy) y5h--00 Big Rock Partners Acquisition Corp. FORM S-4
Released: January 27, 2021
Page: 173
https://fintel.io/doc/sec-big-rock-partners-acquisition-corp-s4-2021-january-27-18654-7
Our first VIP-derived product - ZYESAMI (RLF-100), the NeuroRx COVID-19 Drug - was awarded Fast Track designation by the FDA in June 2020 and admitted to the Coronavirus Treatment Acceleration Program. NeuroRx is currently conducting Phase 2b/3 clinical trials, with read out data expected by January 28, 2021.
With news from Gilles della Corte as well. We should see data very very soon.
Buying MORE !!!
NWBO
0.43 CHF
+0.016 (3.90%)
Jan 25, 9:34 AM
..just noticed.. 0.0002+0.0002 (+1,900.00%) At 3:46PM EST
$APYP ..my.0014's R laying low, Chillin like a bunch'a Villains 'n ain't scared.
Anything Marijuana CBD .. will be swept up in the Positive Reefer madness soon.
$RLFTF - SWX RLF RELIEF THERAPEUTICS Holding SA 0.42 CHF
+0.032 (8.16%)
Jan 21, 5:31 PM
In 2018 this was a shell owned by a group this site doesn't like named but they buy and sell shells and it looks like someone took an interest.. ;) let's hope we get sweeped in a RM that takes care of the commons..
Interesting Relief and Advita Life science
https://twitter.com/NewEma1/status/1351779358944452609?s=20
..this thing is already up 'n running.. I'm surprised.. they're not messing around..
https://jtecautoworld.com/listings/search-results.html
SWX: RLF
0.32 CHF +0.0080 (2.52%)
Jan 19, 5:03 PM
https://www.google.com/search?safe=active&sxsrf=ALeKk03iOFlK23wWQuz4-F4WRO66ZkfN6g%3A1597048446920&source=hp&ei=fgYxX_OVNe2D_Qa6mJ6YAw&q=SWX%3A+RLF&oq=SWX%3A+RLF&gs_lcp=CgZwc3ktYWIQDFC9IVi9IWCaMWgAcAB4AIABWogBWpIBATGYAQCgAQKgAQGqAQdnd3Mtd2l6&sclient=psy-ab&ved=0ahUKEwjzzPWKnZDrAhXtQd8KHTqMBzMQ4dUDCA0
..said I really didn't know jus glanced the ipix board.. and someone said March.. I really don't care.. my reaction was driven by the fud posts of missing out.. not being first.. etc..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160940049
..there's some talk on ipix but I think they start trials in March... we're 2 weeks away and as it's been said we can be rushed through depending on the data... IMO We're the Wabbit not Elmer FUD...
http://www.ipharminc.com/press-release/2021/1/14/innovation-pharmaceuticals-brilacidin-for-the-treatment-of-covid-19-receives-fda-fast-track-designation?fbclid=IwAR1LMqjbRGpYTDudJ8Lam4fJCk5C38p0HnPRcA-8BNIMQjto6hngEcE7aow
..hoping inhaled #RLF-100 #Zyesami #Aviptadil will help deter this outcome..
DD by randychub (copy)
Texas trauma surgeon Dr. Brittany Bankhead-Kendall says it’s a rarity that any of her COVID-19 patients X-rays come back without dense scarring.
In one of her Twitter posts, she says “post-covid lungs look worse than any type of terrible smokers lung
“Everyone’s just so worried about the mortality thing and that’s terrible and it’s awful. But man, and all the survivors and the people who have tested positive this is, it’s going to be a problem,” Dr. Bankhead-Kendall said.
Like many, she’s treated thousands of patients since March.
Of them, she tells CBS 11 News those who have had COVID-19 symptoms show a severe chest X-ray every time. And those who were asymptomatic show a severe chest X-ray 70 to 80% of the time.
“There are still people who say ‘I’m fine I don’t have any issues’ and you pull up their chest X-ray and they absolutely have a bad chest X-ray,” she said.
..mmhh? one foot in MX to do full MJ which may come here in the US also ??
Javitt notes that in their trial enrolled the last patient on December 24, 2020, and they “expect to have the last patient out from the study on January 21, with topline data to follow shortly thereafter.”
The trial’s Data Safety Monitoring Board has reviewed the trial data twice and both times declared it safe to continue. Javitt says, “We expect topline data at the end of the month and that may well trigger regulatory action if we have a positive readout.”
$APYP Marijuana 2014 Resurrection is coming !!!!
$APYP Marijuana 2014 Resurrection is coming !!!!
$RLFTF (related) We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
Learn more: https://prn.to/2XB5QfC
We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
— NRx Pharmaceuticals (@NRxPharma) January 12, 2021
Learn more: https://t.co/xGrP7FsWsm pic.twitter.com/a9d9Xcq7wN
$RLFTF (related) We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
Learn more: https://prn.to/2XB5QfC
We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
— NRx Pharmaceuticals (@NRxPharma) January 12, 2021
Learn more: https://t.co/xGrP7FsWsm pic.twitter.com/a9d9Xcq7wN